The Life Sciences team advised Absci Corporation on a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. AMD made a $20 million investment in Absci, structured as a private investment in public equity, underscoring the growing demand for innovative AI applications in drug discovery. The strategic partnership supports Absci’s mission of creating better biologics for patients, faster by providing optimized AI solutions for complex biological modeling that offer exceptional performance, reduced infrastructure costs, and faster innovation cycles. Absci and AMD entered into a memorandum of understanding (“MOU”) pursuant to which Absci agreed to transfer its cloud-based AI development activities to AMD GPUs subject to such hardware meeting or exceeding minimum performance criteria and cost efficiency requirements specified in the MOU.
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Absci’s Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, Absci can screen billions of cells per week, allowing the Company to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.
The deal team was led by Marianne Sarrazin, Evan Lee, Maggie Wong and Kingsley Taft with invaluable assistance from Tricia Hojo and Ruowen Li. Robert Crawford and Shannyn Henke advised Absci with respect to the MOU.
For more information on the deal, please read the press release.
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Absci’s Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, Absci can screen billions of cells per week, allowing the Company to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.
The deal team was led by Marianne Sarrazin, Evan Lee, Maggie Wong and Kingsley Taft with invaluable assistance from Tricia Hojo and Ruowen Li. Robert Crawford and Shannyn Henke advised Absci with respect to the MOU.
For more information on the deal, please read the press release.